NORTH AMERICA BIOCHIPS MARKET FORECAST 2018-2026
KEY FINDINGS
North America Biochips market is expected to evolve with 20.72% CAGR over the forecast period of 2018-2026. North America has been on the forefront in the various application segment. North America’s leading position in the healthcare and the life science industry makes it an important geographic market for biochips
MARKET INSIGHTS
Biochip has several applications in the field of medicine, biosciences, biotechnology and molecular biology. In the medical industry, biochips are mostly used for drug discovery and for producing biomarkers. Investments by organizations like DARPA, NIH and the FDA to speed up the development of biochips in the U.S is acting as a major boosting factor for the market. Also, several key companies in this region are investing heavily in the biochips technology. On the other hand, venture capital funding by Turnstone Biologics in order to improve the R&D activities in the Canadian biotechnology sector, combined with the rising healthcare expenditure is expected to drive the growth across the Canada biochip market over the forecast period.
COMPETITIVE INSIGHTS
Noted companies in this market are Thermo Fisher Scientific Inc, Illumina Inc, Biochain Institute Inc, Perkinelmer Inc, Biomerieux SA, Origene Technologies Inc, Fluidigm Corporation, Agilent Technology Inc, Cepheid Inc, Merck Gmbh, Samsung Electronics Inc, Bio-Rad Laboratories Inc, amongst others.
North America Biochips market is expected to evolve with 20.72% CAGR over the forecast period of 2018-2026. North America has been on the forefront in the various application segment. North America’s leading position in the healthcare and the life science industry makes it an important geographic market for biochips
MARKET INSIGHTS
Biochip has several applications in the field of medicine, biosciences, biotechnology and molecular biology. In the medical industry, biochips are mostly used for drug discovery and for producing biomarkers. Investments by organizations like DARPA, NIH and the FDA to speed up the development of biochips in the U.S is acting as a major boosting factor for the market. Also, several key companies in this region are investing heavily in the biochips technology. On the other hand, venture capital funding by Turnstone Biologics in order to improve the R&D activities in the Canadian biotechnology sector, combined with the rising healthcare expenditure is expected to drive the growth across the Canada biochip market over the forecast period.
COMPETITIVE INSIGHTS
Noted companies in this market are Thermo Fisher Scientific Inc, Illumina Inc, Biochain Institute Inc, Perkinelmer Inc, Biomerieux SA, Origene Technologies Inc, Fluidigm Corporation, Agilent Technology Inc, Cepheid Inc, Merck Gmbh, Samsung Electronics Inc, Bio-Rad Laboratories Inc, amongst others.
1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP-DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. NORTH AMERICA DOMINATES THE OVERALL BIOCHIPS MARKET
3.2.2. DNA CHIPS ACCOUNTS FOR THE LARGEST REVENUE SHARE OF BIOCHIPS MARKET BY TYPE SEGMENT
3.2.3. HOSPITALS & DIAGNOSTICS CENTERS – KEY END USER VERTICALS
3.2.4. PROTEIN CHIP IN THE TYPE SEGMENT IS PROJECTED TO RISE WITH THE HIGHEST GROWTH RATE
4. MARKET DYNAMICS
4.1. PARENT MARKET ANALYSIS: GENOMICS AND PROTEOMICS MARKET
4.2. ETYMOLOGY OF BIOCHIPS MARKET
4.3. MARKET DEFINITION & SCOPE
4.4. DRIVERS
4.4.1. INCREASING PREVALENCE OF CANCER
4.4.2. INCREASED GOVERNMENT FUNDING, R&D INVESTMENT IN BIOTECHNOLOGY
4.4.3. GROWING INTEREST IN PERSONALIZED MEDICINES
4.4.4. SIGNIFICANT GROWTH IN THE HEALTHCARE EXPENDITURE ACROSS GEOGRAPHIES
4.5. RESTRAINTS
4.5.1. LACK OF HEALTHCARE COVERAGE
4.5.2. AVAILABILITY OF ALTERNATIVE TECHNOLOGY: NEXT GENERATION SEQUENCING (NGS) TECHNOLOGY
4.5.3. LACK OF AWARENESS ABOUT BIOCHIP TECHNOLOGY
4.6. OPPORTUNITIES
4.6.1. TECHNOLOGICAL ADVANCEMENT IN BIOTECHNOLOGY
4.6.2. GROWING APPLICATIONS OF BIOCHIPS
4.7. CHALLENGES
4.7.1. COMPLEXITY OF BIOLOGICAL SYSTEMS
4.7.2. LACK OF COMMON REGULATORY STANDARDS
4.7.3. HIGH INSTRUMENTATION COST
5. MARKET BY TYPE
5.1. DNA CHIPS
5.1.1. AGRICULTURAL BIOTECHNOLOGY
5.1.2. CANCER DIAGNOSTICS & TREATMENT
5.1.3. DRUG DISCOVERY
5.1.4. GENE EXPRESSION
5.1.5. GENOMICS
5.1.6. SINGLE NUCLEOTIDE POLYMORPHISM (SNP) GENOTYPING
5.1.7. OTHER DNA CHIPS
5.2. LAB ON A CHIP
5.2.1. CLINICAL DIAGNOSTICS
5.2.2. DRUG DISCOVERY
5.2.3. GENOMICS
5.2.4. POINT OF CARE (POC) & IN VITRO DIAGNOSIS (IVS)
5.2.5. PROTEOMICS
5.2.6. OTHER LAB ON A CHIP
5.3. PROTEIN CHIPS
5.3.1. DIAGNOSTICS
5.3.2. DRUG DISCOVERY
5.3.3. EXPRESSION PROFILING
5.3.4. HIGH THROUGHPUT SCREENING
5.3.5. PROTEOMICS
5.3.6. OTHER PROTEIN CHIPS
5.4. OTHER CHIPS
5.4.1. CELL ARRAYS
5.4.2. TISSUE ARRAYS
6. MARKET BY SUBSTRATE MATERIALS
6.1. GLASS
6.2. POLYMERS
6.3. SILICON
6.4. OTHER SUBSTRATE MATERIALS
7. MARKET BY END USERS
7.1. BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES
7.2. HOSPITALS AND DIAGNOSTICS CENTERS
7.3. ACADEMIC AND RESEARCH INSTITUTE
8. KEY ANALYTICS
8.1. PORTER’S FIVE FORCE MODEL
8.1.1. THREAT OF NEW ENTRANTS
8.1.2. THREAT OF SUBSTITUTE
8.1.3. BARGAINING POWER OF SUPPLIERS
8.1.4. BARGAINING POWER OF BUYERS
8.1.5. THREAT OF COMPETITIVE RIVALRY
8.2. OPPORTUNITY MATRIX
8.3. VENDOR LANDSCAPE
8.4. VALUE CHAIN ANALYSIS
8.4.1. RESEARCH & DEVELOPMENT
8.4.2. RAW MATERIALS
8.4.3. MANUFACTURING
8.4.4. WHOLESALERS/RETAILERS/DISTRIBUTORS
8.4.5. END USERS
8.5. LEGAL, POLICY & REGULATORY FRAMEWORK
8.6. KEY BUYING CRITERIA
8.6.1. COST
8.6.2. APPLICATIONS
8.6.3. PRODUCT TYPE
8.7. INVESTMENT ANALYSIS
8.7.1. OPPORTUNITIES BY END-USER SEGMENT
8.7.2. OPPORTUNITIES BY BIOCHIP TYPE SEGMENT
9. GEOGRAPHICAL ANALYSIS
9.1. UNITED STATES
9.2. CANADA
10. COMPETITIVE LANDSCAPE
10.1. MARKET SHARE ANALYSIS
10.2. KEY COMPANY ANALYSIS
10.2.1. MERCK GMBH
10.2.2. AGILENT TECHNOLOGY INC.
10.2.3. ILLUMINA INC.
10.2.4. THERMO FISHER SCIENTIFIC INC.
10.3. CORPORATE STRATEGIES
10.3.1. PARTNERSHIP & COLLABORATION
10.3.2. MERGERS AND ACQUISITIONS
10.4. COMPANY PROFILES
10.4.1. AGILENT TECHNOLOGY INC.
10.4.2. BIOCHAIN INSTITUTE INC.
10.4.3. BIOMERIEUX SA
10.4.4. BIO-RAD LABORATORIES INC.
10.4.5. CEPHEID INC.
10.4.6. CYBRDI INC.
10.4.7. FLUIDIGM CORPORATION
10.4.8. GAMIDA FOR LIFE GROUP
10.4.9. ILLUMINA INC.
10.4.10. IMGENEX
10.4.11. MERCK GMBH
10.4.12. ORIGENE TECHNOLOGIES INC.
10.4.13. PERKINELMER INC.
10.4.14. SAMSUNG ELECTRONICS INC.
10.4.15. THERMO FISHER SCIENTIFIC INC.
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP-DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. NORTH AMERICA DOMINATES THE OVERALL BIOCHIPS MARKET
3.2.2. DNA CHIPS ACCOUNTS FOR THE LARGEST REVENUE SHARE OF BIOCHIPS MARKET BY TYPE SEGMENT
3.2.3. HOSPITALS & DIAGNOSTICS CENTERS – KEY END USER VERTICALS
3.2.4. PROTEIN CHIP IN THE TYPE SEGMENT IS PROJECTED TO RISE WITH THE HIGHEST GROWTH RATE
4. MARKET DYNAMICS
4.1. PARENT MARKET ANALYSIS: GENOMICS AND PROTEOMICS MARKET
4.2. ETYMOLOGY OF BIOCHIPS MARKET
4.3. MARKET DEFINITION & SCOPE
4.4. DRIVERS
4.4.1. INCREASING PREVALENCE OF CANCER
4.4.2. INCREASED GOVERNMENT FUNDING, R&D INVESTMENT IN BIOTECHNOLOGY
4.4.3. GROWING INTEREST IN PERSONALIZED MEDICINES
4.4.4. SIGNIFICANT GROWTH IN THE HEALTHCARE EXPENDITURE ACROSS GEOGRAPHIES
4.5. RESTRAINTS
4.5.1. LACK OF HEALTHCARE COVERAGE
4.5.2. AVAILABILITY OF ALTERNATIVE TECHNOLOGY: NEXT GENERATION SEQUENCING (NGS) TECHNOLOGY
4.5.3. LACK OF AWARENESS ABOUT BIOCHIP TECHNOLOGY
4.6. OPPORTUNITIES
4.6.1. TECHNOLOGICAL ADVANCEMENT IN BIOTECHNOLOGY
4.6.2. GROWING APPLICATIONS OF BIOCHIPS
4.7. CHALLENGES
4.7.1. COMPLEXITY OF BIOLOGICAL SYSTEMS
4.7.2. LACK OF COMMON REGULATORY STANDARDS
4.7.3. HIGH INSTRUMENTATION COST
5. MARKET BY TYPE
5.1. DNA CHIPS
5.1.1. AGRICULTURAL BIOTECHNOLOGY
5.1.2. CANCER DIAGNOSTICS & TREATMENT
5.1.3. DRUG DISCOVERY
5.1.4. GENE EXPRESSION
5.1.5. GENOMICS
5.1.6. SINGLE NUCLEOTIDE POLYMORPHISM (SNP) GENOTYPING
5.1.7. OTHER DNA CHIPS
5.2. LAB ON A CHIP
5.2.1. CLINICAL DIAGNOSTICS
5.2.2. DRUG DISCOVERY
5.2.3. GENOMICS
5.2.4. POINT OF CARE (POC) & IN VITRO DIAGNOSIS (IVS)
5.2.5. PROTEOMICS
5.2.6. OTHER LAB ON A CHIP
5.3. PROTEIN CHIPS
5.3.1. DIAGNOSTICS
5.3.2. DRUG DISCOVERY
5.3.3. EXPRESSION PROFILING
5.3.4. HIGH THROUGHPUT SCREENING
5.3.5. PROTEOMICS
5.3.6. OTHER PROTEIN CHIPS
5.4. OTHER CHIPS
5.4.1. CELL ARRAYS
5.4.2. TISSUE ARRAYS
6. MARKET BY SUBSTRATE MATERIALS
6.1. GLASS
6.2. POLYMERS
6.3. SILICON
6.4. OTHER SUBSTRATE MATERIALS
7. MARKET BY END USERS
7.1. BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES
7.2. HOSPITALS AND DIAGNOSTICS CENTERS
7.3. ACADEMIC AND RESEARCH INSTITUTE
8. KEY ANALYTICS
8.1. PORTER’S FIVE FORCE MODEL
8.1.1. THREAT OF NEW ENTRANTS
8.1.2. THREAT OF SUBSTITUTE
8.1.3. BARGAINING POWER OF SUPPLIERS
8.1.4. BARGAINING POWER OF BUYERS
8.1.5. THREAT OF COMPETITIVE RIVALRY
8.2. OPPORTUNITY MATRIX
8.3. VENDOR LANDSCAPE
8.4. VALUE CHAIN ANALYSIS
8.4.1. RESEARCH & DEVELOPMENT
8.4.2. RAW MATERIALS
8.4.3. MANUFACTURING
8.4.4. WHOLESALERS/RETAILERS/DISTRIBUTORS
8.4.5. END USERS
8.5. LEGAL, POLICY & REGULATORY FRAMEWORK
8.6. KEY BUYING CRITERIA
8.6.1. COST
8.6.2. APPLICATIONS
8.6.3. PRODUCT TYPE
8.7. INVESTMENT ANALYSIS
8.7.1. OPPORTUNITIES BY END-USER SEGMENT
8.7.2. OPPORTUNITIES BY BIOCHIP TYPE SEGMENT
9. GEOGRAPHICAL ANALYSIS
9.1. UNITED STATES
9.2. CANADA
10. COMPETITIVE LANDSCAPE
10.1. MARKET SHARE ANALYSIS
10.2. KEY COMPANY ANALYSIS
10.2.1. MERCK GMBH
10.2.2. AGILENT TECHNOLOGY INC.
10.2.3. ILLUMINA INC.
10.2.4. THERMO FISHER SCIENTIFIC INC.
10.3. CORPORATE STRATEGIES
10.3.1. PARTNERSHIP & COLLABORATION
10.3.2. MERGERS AND ACQUISITIONS
10.4. COMPANY PROFILES
10.4.1. AGILENT TECHNOLOGY INC.
10.4.2. BIOCHAIN INSTITUTE INC.
10.4.3. BIOMERIEUX SA
10.4.4. BIO-RAD LABORATORIES INC.
10.4.5. CEPHEID INC.
10.4.6. CYBRDI INC.
10.4.7. FLUIDIGM CORPORATION
10.4.8. GAMIDA FOR LIFE GROUP
10.4.9. ILLUMINA INC.
10.4.10. IMGENEX
10.4.11. MERCK GMBH
10.4.12. ORIGENE TECHNOLOGIES INC.
10.4.13. PERKINELMER INC.
10.4.14. SAMSUNG ELECTRONICS INC.
10.4.15. THERMO FISHER SCIENTIFIC INC.
LIST OF TABLES
TABLE 1: NORTH AMERICA BIOCHIPS MARKET, BY GEOGRAPHY, 2018-2026 (IN $ MILLION)
TABLE 2: ESTIMATED NUMBER OF NEW CANCER CASES & ESTIMATED DEATHS DUE TO CANCER IN UNITED STATES IN 2017
TABLE 3: NOTABLE INVESTMENTS MADE IN BIOTECHNOLOGY INDUSTRY IN 2017
TABLE 4: ESTIMATED R&D EXPENDITURE IN MEDICAL & HEALTHCARE INDUSTRY OF UNITED STATES, 2013-2015 (IN $ MILLIONS)
TABLE 5: ESTIMATED R&D SPENDING IN BIOTECHNOLOGY, PHARMACEUTICAL, & MEDICAL INDUSTRY OF UNITED STATES, 2013-2015 (IN $ MILLIONS)
TABLE 6: NORTH AMERICA BIOCHIPS MARKET, BY TYPE, 2018-2026, (IN $ MILLION)
TABLE 7: NORTH AMERICA DNA CHIPS MARKET, BY APPLICATIONS, 2018-2026 (IN $ MILLION)
TABLE 8: NORTH AMERICA LAB ON A CHIP MARKET, BY APPLICATIONS, 2018-2026 (IN $ MILLION)
TABLE 9: NORTH AMERICA PROTEIN CHIPS MARKET, BY APPLICATIONS, 2018-2026 (IN $ MILLION)
TABLE 10: NORTH AMERICA OTHER CHIPS MARKET, BY APPLICATIONS, 2018-2026 (IN $ MILLION)
TABLE 11: NORTH AMERICA BIOCHIPS MARKET, BY SUBSTRATE MATERIALS, 2018-2026 (IN $ MILLIONS)
TABLE 12: PROPERTIES OF BIOCHIPS SUBSTRATE MATERIALS
TABLE 13: NORTH AMERICA BIOCHIPS MARKET, BY END USERS, 2018-2026 (IN $ MILLIONS)
TABLE 14: OPPORTUNITY MATRIX FOR BIOCHIPS MARKET
TABLE 15: VENDOR LANDSCAPE OF BIOCHIPS MARKET
TABLE 16: LEGAL, POLICY & REGULATORY FRAMEWORK OF BIOCHIPS MARKET
TABLE 17: NORTH AMERICA BIOCHIPS MARKET, BY COUNTRY, 2018-2026 (IN $ MILLION)
TABLE 18: LIST OF PARTNERSHIP & COLLABORATION
TABLE 19: LIST OF MERGERS AND ACQUISITIONS
TABLE 1: NORTH AMERICA BIOCHIPS MARKET, BY GEOGRAPHY, 2018-2026 (IN $ MILLION)
TABLE 2: ESTIMATED NUMBER OF NEW CANCER CASES & ESTIMATED DEATHS DUE TO CANCER IN UNITED STATES IN 2017
TABLE 3: NOTABLE INVESTMENTS MADE IN BIOTECHNOLOGY INDUSTRY IN 2017
TABLE 4: ESTIMATED R&D EXPENDITURE IN MEDICAL & HEALTHCARE INDUSTRY OF UNITED STATES, 2013-2015 (IN $ MILLIONS)
TABLE 5: ESTIMATED R&D SPENDING IN BIOTECHNOLOGY, PHARMACEUTICAL, & MEDICAL INDUSTRY OF UNITED STATES, 2013-2015 (IN $ MILLIONS)
TABLE 6: NORTH AMERICA BIOCHIPS MARKET, BY TYPE, 2018-2026, (IN $ MILLION)
TABLE 7: NORTH AMERICA DNA CHIPS MARKET, BY APPLICATIONS, 2018-2026 (IN $ MILLION)
TABLE 8: NORTH AMERICA LAB ON A CHIP MARKET, BY APPLICATIONS, 2018-2026 (IN $ MILLION)
TABLE 9: NORTH AMERICA PROTEIN CHIPS MARKET, BY APPLICATIONS, 2018-2026 (IN $ MILLION)
TABLE 10: NORTH AMERICA OTHER CHIPS MARKET, BY APPLICATIONS, 2018-2026 (IN $ MILLION)
TABLE 11: NORTH AMERICA BIOCHIPS MARKET, BY SUBSTRATE MATERIALS, 2018-2026 (IN $ MILLIONS)
TABLE 12: PROPERTIES OF BIOCHIPS SUBSTRATE MATERIALS
TABLE 13: NORTH AMERICA BIOCHIPS MARKET, BY END USERS, 2018-2026 (IN $ MILLIONS)
TABLE 14: OPPORTUNITY MATRIX FOR BIOCHIPS MARKET
TABLE 15: VENDOR LANDSCAPE OF BIOCHIPS MARKET
TABLE 16: LEGAL, POLICY & REGULATORY FRAMEWORK OF BIOCHIPS MARKET
TABLE 17: NORTH AMERICA BIOCHIPS MARKET, BY COUNTRY, 2018-2026 (IN $ MILLION)
TABLE 18: LIST OF PARTNERSHIP & COLLABORATION
TABLE 19: LIST OF MERGERS AND ACQUISITIONS
LIST OF FIGURES
FIGURE 1: NORTH AMERICA BIOCHIPS MARKET, BY END USERS, 2017 & 2026 (IN %)
FIGURE 2: NORTH AMERICA BIOCHIPS MARKET, 2018-2026 (IN $ MILLION)
FIGURE 3: EVOLUTION & TRANSITION OF BIOCHIPS
FIGURE 4: WORLDWIDE HEALTHCARE SPENDING, BY REGIONS, 2014-2015 (% OF GDP)
FIGURE 5: UNITED STATES HEALTHCARE SPENDING, 2015-2025 (% OF GDP)
FIGURE 6: COMPARISON OF HEALTHCARE SPENDING PER CAPITA AND OUT OF THE POCKET HEALTH EXPENDITURE
FIGURE 7: NORTH AMERICA BIOCHIPS MARKET, BY DNA CHIPS, 2018-2026 (IN $ MILLION)
FIGURE 8: NORTH AMERICA DNA CHIPS MARKET, BY AGRICULTURAL BIOTECHNOLOGY, 2018-2026 (IN $ MILLION)
FIGURE 9: NORTH AMERICA DNA CHIPS MARKET, BY CANCER DIAGNOSTICS & TREATMENT, 2018-2026 (IN $ MILLION)
FIGURE 10: NORTH AMERICA DNA CHIPS MARKET, BY DRUG DISCOVERY, 2018-2026 (IN $ MILLION)
FIGURE 11: NORTH AMERICA DNA CHIPS MARKET, BY GENE EXPRESSION, 2018-2026 (IN $ MILLION)
FIGURE 12: NORTH AMERICA DNA CHIPS MARKET, BY GENOMICS, 2018-2026 (IN $ MILLION)
FIGURE 13: NORTH AMERICA DNA CHIPS MARKET, BY SINGLE NUCLEOTIDE POLYMORPHISM (SNP) GENOTYPING, 2018-2026 (IN $ MILLION)
FIGURE 14: NORTH AMERICA DNA CHIPS MARKET, BY OTHER CHIPS, 2018-2026 (IN $ MILLION)
FIGURE 15: NORTH AMERICA BIOCHIPS MARKET, BY LAB ON A CHIP, 2018-2026 (IN $ MILLION)
FIGURE 16: NORTH AMERICA LAB ON A CHIP MARKET, BY CLINICAL DIAGNOSTICS, 2018-2026 (IN $ MILLION)
FIGURE 17: NORTH AMERICA LAB ON A CHIP MARKET, BY DRUG DISCOVERY, 2018-2026 (IN $ MILLION)
FIGURE 18: NORTH AMERICA LAB ON A CHIP MARKET, BY GENOMICS, 2018-2026 (IN $ MILLION)
FIGURE 19: NORTH AMERICA LAB ON A CHIP MARKET, BY POINT OF CARE (POC) & IN VITRO DIAGNOSIS (IVS), 2018-2026 (IN $ MILLION)
FIGURE 20: NORTH AMERICA LAB ON A CHIP MARKET, BY PROTEOMICS, 2018-2026 (IN $ MILLION)
FIGURE 21: NORTH AMERICA LAB ON A CHIP MARKET, BY OTHER LAB ON A CHIP, 2018-2026 (IN $ MILLION)
FIGURE 22: NORTH AMERICA BIOCHIPS MARKET, BY PROTEIN CHIPS, 2018-2026 (IN $ MILLION)
FIGURE 23: NORTH AMERICA PROTEIN CHIPS MARKET, BY DIAGNOSTICS, 2018-2026 (IN $ MILLION)
FIGURE 24: NORTH AMERICA PROTEIN CHIPS MARKET, BY DRUG DISCOVERY, 2018-2026 (IN $ MILLION)
FIGURE 25: NORTH AMERICA PROTEIN CHIPS MARKET, BY EXPRESSION PROFILING, 2018-2026 (IN $ MILLION)
FIGURE 26: NORTH AMERICA PROTEIN CHIPS MARKET, BY HIGH THROUGHPUT SCREENING, 2018-2026 (IN $ MILLION)
FIGURE 27: NORTH AMERICA PROTEIN CHIPS MARKET, BY PROTEOMICS, 2018-2026 (IN $ MILLION)
FIGURE 28: NORTH AMERICA PROTEIN CHIPS MARKET, BY OTHER PROTEIN CHIPS, 2018-2026 (IN $ MILLION)
FIGURE 29: NORTH AMERICA BIOCHIPS MARKET, BY OTHER CHIPS, 2018-2026 (IN $ MILLION)
FIGURE 30: NORTH AMERICA OTHER BIOCHIPS MARKET, BY CELL ARRAYS, 2018-2026 (IN $ MILLION)
FIGURE 31: NORTH AMERICA OTHER BIOCHIPS MARKET, BY TISSUE ARRAYS, 2018-2026 (IN $ MILLION)
FIGURE 32: NORTH AMERICA BIOCHIPS MARKET, BY GLASS, 2018-2026 (IN $ MILLIONS)
FIGURE 33: NORTH AMERICA BIOCHIPS MARKET, BY POLYMERS, 2018-2026 (IN $ MILLIONS)
FIGURE 34: NORTH AMERICA BIOCHIPS MARKET, BY SILICON, 2018-2026 (IN $ MILLIONS)
FIGURE 35: NORTH AMERICA BIOCHIPS MARKET, BY OTHER SUBSTRATE MATERIALS, 2018-2026 (IN $ MILLIONS)
FIGURE 36: NORTH AMERICA BIOCHIPS MARKET, BY BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES, 2018-2026 (IN $ MILLIONS)
FIGURE 37: NORTH AMERICA BIOCHIPS MARKET, BY HOSPITALS AND DIAGNOSTICS CENTERS, 2018-2026 (IN $ MILLIONS)
FIGURE 38: NORTH AMERICA BIOCHIPS MARKET, BY ACADEMIC AND RESEARCH INSTITUTE, 2018-2026 (IN $ MILLIONS)
FIGURE 39: PORTER’S FIVE FORCE MODEL OF BIOCHIPS MARKET
FIGURE 40: VALUE CHAIN OF BIOCHIPS MARKET
FIGURE 41: KEY IMPACT ANALYSIS
FIGURE 42: INVESTMENT OPPORTUNITIES IN BIOCHIPS MARKET, BY END-USER SEGMENT
FIGURE 43: INVESTMENT OPPORTUNITIES IN BIOCHIPS MARKET, BY TYPE SEGMENT
FIGURE 44: NORTH AMERICA BIOCHIPS MARKET, REGIONAL OUTLOOK, 2017 & 2026 (IN %)
FIGURE 45: UNITED STATES BIOCHIPS MARKET, 2018-2026 (IN $ MILLION)
FIGURE 46: CANADA BIOCHIPS MARKET, 2018-2026 (IN $ MILLION)
FIGURE 47: MARKET SHARE ANALYSIS OF KEY PLAYERS IN 2017 (%)
COMPANIES MENTIONED
1. AGILENT TECHNOLOGY INC.
2. BIOCHAIN INSTITUTE INC.
3. BIOMERIEUX SA
4. BIO-RAD LABORATORIES INC.
5. CEPHEID INC.
6. CYBRDI INC.
7. FLUIDIGM CORPORATION
8. GAMIDA FOR LIFE GROUP
9. ILLUMINA INC.
10. IMGENEX
11. MERCK GMBH
12. ORIGENE TECHNOLOGIES INC.
13. PERKINELMER INC.
14. SAMSUNG ELECTRONICS INC.
15. THERMO FISHER SCIENTIFIC INC.
FIGURE 1: NORTH AMERICA BIOCHIPS MARKET, BY END USERS, 2017 & 2026 (IN %)
FIGURE 2: NORTH AMERICA BIOCHIPS MARKET, 2018-2026 (IN $ MILLION)
FIGURE 3: EVOLUTION & TRANSITION OF BIOCHIPS
FIGURE 4: WORLDWIDE HEALTHCARE SPENDING, BY REGIONS, 2014-2015 (% OF GDP)
FIGURE 5: UNITED STATES HEALTHCARE SPENDING, 2015-2025 (% OF GDP)
FIGURE 6: COMPARISON OF HEALTHCARE SPENDING PER CAPITA AND OUT OF THE POCKET HEALTH EXPENDITURE
FIGURE 7: NORTH AMERICA BIOCHIPS MARKET, BY DNA CHIPS, 2018-2026 (IN $ MILLION)
FIGURE 8: NORTH AMERICA DNA CHIPS MARKET, BY AGRICULTURAL BIOTECHNOLOGY, 2018-2026 (IN $ MILLION)
FIGURE 9: NORTH AMERICA DNA CHIPS MARKET, BY CANCER DIAGNOSTICS & TREATMENT, 2018-2026 (IN $ MILLION)
FIGURE 10: NORTH AMERICA DNA CHIPS MARKET, BY DRUG DISCOVERY, 2018-2026 (IN $ MILLION)
FIGURE 11: NORTH AMERICA DNA CHIPS MARKET, BY GENE EXPRESSION, 2018-2026 (IN $ MILLION)
FIGURE 12: NORTH AMERICA DNA CHIPS MARKET, BY GENOMICS, 2018-2026 (IN $ MILLION)
FIGURE 13: NORTH AMERICA DNA CHIPS MARKET, BY SINGLE NUCLEOTIDE POLYMORPHISM (SNP) GENOTYPING, 2018-2026 (IN $ MILLION)
FIGURE 14: NORTH AMERICA DNA CHIPS MARKET, BY OTHER CHIPS, 2018-2026 (IN $ MILLION)
FIGURE 15: NORTH AMERICA BIOCHIPS MARKET, BY LAB ON A CHIP, 2018-2026 (IN $ MILLION)
FIGURE 16: NORTH AMERICA LAB ON A CHIP MARKET, BY CLINICAL DIAGNOSTICS, 2018-2026 (IN $ MILLION)
FIGURE 17: NORTH AMERICA LAB ON A CHIP MARKET, BY DRUG DISCOVERY, 2018-2026 (IN $ MILLION)
FIGURE 18: NORTH AMERICA LAB ON A CHIP MARKET, BY GENOMICS, 2018-2026 (IN $ MILLION)
FIGURE 19: NORTH AMERICA LAB ON A CHIP MARKET, BY POINT OF CARE (POC) & IN VITRO DIAGNOSIS (IVS), 2018-2026 (IN $ MILLION)
FIGURE 20: NORTH AMERICA LAB ON A CHIP MARKET, BY PROTEOMICS, 2018-2026 (IN $ MILLION)
FIGURE 21: NORTH AMERICA LAB ON A CHIP MARKET, BY OTHER LAB ON A CHIP, 2018-2026 (IN $ MILLION)
FIGURE 22: NORTH AMERICA BIOCHIPS MARKET, BY PROTEIN CHIPS, 2018-2026 (IN $ MILLION)
FIGURE 23: NORTH AMERICA PROTEIN CHIPS MARKET, BY DIAGNOSTICS, 2018-2026 (IN $ MILLION)
FIGURE 24: NORTH AMERICA PROTEIN CHIPS MARKET, BY DRUG DISCOVERY, 2018-2026 (IN $ MILLION)
FIGURE 25: NORTH AMERICA PROTEIN CHIPS MARKET, BY EXPRESSION PROFILING, 2018-2026 (IN $ MILLION)
FIGURE 26: NORTH AMERICA PROTEIN CHIPS MARKET, BY HIGH THROUGHPUT SCREENING, 2018-2026 (IN $ MILLION)
FIGURE 27: NORTH AMERICA PROTEIN CHIPS MARKET, BY PROTEOMICS, 2018-2026 (IN $ MILLION)
FIGURE 28: NORTH AMERICA PROTEIN CHIPS MARKET, BY OTHER PROTEIN CHIPS, 2018-2026 (IN $ MILLION)
FIGURE 29: NORTH AMERICA BIOCHIPS MARKET, BY OTHER CHIPS, 2018-2026 (IN $ MILLION)
FIGURE 30: NORTH AMERICA OTHER BIOCHIPS MARKET, BY CELL ARRAYS, 2018-2026 (IN $ MILLION)
FIGURE 31: NORTH AMERICA OTHER BIOCHIPS MARKET, BY TISSUE ARRAYS, 2018-2026 (IN $ MILLION)
FIGURE 32: NORTH AMERICA BIOCHIPS MARKET, BY GLASS, 2018-2026 (IN $ MILLIONS)
FIGURE 33: NORTH AMERICA BIOCHIPS MARKET, BY POLYMERS, 2018-2026 (IN $ MILLIONS)
FIGURE 34: NORTH AMERICA BIOCHIPS MARKET, BY SILICON, 2018-2026 (IN $ MILLIONS)
FIGURE 35: NORTH AMERICA BIOCHIPS MARKET, BY OTHER SUBSTRATE MATERIALS, 2018-2026 (IN $ MILLIONS)
FIGURE 36: NORTH AMERICA BIOCHIPS MARKET, BY BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES, 2018-2026 (IN $ MILLIONS)
FIGURE 37: NORTH AMERICA BIOCHIPS MARKET, BY HOSPITALS AND DIAGNOSTICS CENTERS, 2018-2026 (IN $ MILLIONS)
FIGURE 38: NORTH AMERICA BIOCHIPS MARKET, BY ACADEMIC AND RESEARCH INSTITUTE, 2018-2026 (IN $ MILLIONS)
FIGURE 39: PORTER’S FIVE FORCE MODEL OF BIOCHIPS MARKET
FIGURE 40: VALUE CHAIN OF BIOCHIPS MARKET
FIGURE 41: KEY IMPACT ANALYSIS
FIGURE 42: INVESTMENT OPPORTUNITIES IN BIOCHIPS MARKET, BY END-USER SEGMENT
FIGURE 43: INVESTMENT OPPORTUNITIES IN BIOCHIPS MARKET, BY TYPE SEGMENT
FIGURE 44: NORTH AMERICA BIOCHIPS MARKET, REGIONAL OUTLOOK, 2017 & 2026 (IN %)
FIGURE 45: UNITED STATES BIOCHIPS MARKET, 2018-2026 (IN $ MILLION)
FIGURE 46: CANADA BIOCHIPS MARKET, 2018-2026 (IN $ MILLION)
FIGURE 47: MARKET SHARE ANALYSIS OF KEY PLAYERS IN 2017 (%)
COMPANIES MENTIONED
1. AGILENT TECHNOLOGY INC.
2. BIOCHAIN INSTITUTE INC.
3. BIOMERIEUX SA
4. BIO-RAD LABORATORIES INC.
5. CEPHEID INC.
6. CYBRDI INC.
7. FLUIDIGM CORPORATION
8. GAMIDA FOR LIFE GROUP
9. ILLUMINA INC.
10. IMGENEX
11. MERCK GMBH
12. ORIGENE TECHNOLOGIES INC.
13. PERKINELMER INC.
14. SAMSUNG ELECTRONICS INC.
15. THERMO FISHER SCIENTIFIC INC.
